| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701567 | Journal of Thoracic Oncology | 2017 | 26 Pages |
Abstract
Maintenance sunitinib was safe and improved PFS as maintenance therapy in stage IIIB/IV NSCLC but had no impact on overall survival. There is no room for future investigations of sunitinib in this setting.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Maria Q. MD, Mark A. MD, Xiaofei F. PhD, Lin MS, Thomas E. MD, Martin J. MD, Sherman MD, Josephine MD, Paul MS, Olwen MD, Jeffrey A. MD, Everett E. MD,